White DL, Saunders VA, Dang P, Frede A, Eadie LN, Soverini S, Quarantelli F, Lin P, Thornquist M, Kim D-W, Pane F, Martinelli G, Radich J, Kalebic T, Saglio G, Hughes T. CML patients with low OCT-1 activity achieve better molecular responses on high dose imatinib than on standard dose. Those with high OCT-1 activity have excellent responses on either dose: a TOPS correlative study. Poster Presentation San Francisco, California